Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Starting soon · Phase 1/Phase 2

Conditions studied: B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

In brief

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Key facts

Study ID

NCT07520006

Run by

Nurix Therapeutics, Inc.

People needed

150

Starts

2026-05-01

Expected to finish

2033-05-01

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.